<DOC>
	<DOCNO>NCT02550106</DOCNO>
	<brief_summary>Evaluate proportion patient urticaria control test [ UCT ] score great equal 12 Week 12 .</brief_summary>
	<brief_title>Omalizumab Chronic Spontaneous Urticaria Patients Non Responding Initial Standard antihistaminE Treatment</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Male female patient age 18 75 year . Diagnosis CSU â‰¥ 6 month inadequate response nsH1 antihistamine time request , define follow : The presence itch hive &gt; 6 consecutive week time prior enrollment , despite current use H1 antihistamine therapy time period . Weekly UAS7 score ( range 0 42 ) 16 UCT score ( range 0 16 ) &lt; 8 prior enrollment ( Day 1 ) Current use H1 antihistamine CSU day initial visit Day Informed consent Treatment investigational agent within 30 day enrollment . Routine ( daily every day 5 consecutive day ) dose follow medication within 30 day prior Day 7 : systemic cutaneous ( topical ) corticosteroid ( prescription counter ) , hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide . Intravenous ( i.v . ) immunoglobulin G plasmapheresis within 30 day prior Day 7 Regular ( daily/every day ) doxepin ( oral ) use within 14 day prior Day 7 . Any H2 antihistamine use within 7 day prior Day 7 . Any leukotriene receptor antagonist ( LTRA ) ( montelukast zafirlukast ) within 7 day prior Day 7 . Concomitant use cyclosporine immunosuppressive agent . Hypersensitivity omalizumab component formulation . History anaphylactic shock .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CHRONIC SPONTANEOUS URTICARIA , OMALIZUMAB , URTICARIA CONTROL TEST</keyword>
</DOC>